The overall objective of the BioPrintIA project is the industrial research of a new treatment based on the generation of novel cellularised, functionalised, and personalised bioimplants using innovative technologies such as artificial intelligence and 3D bioprinting. This approach aims to enable the transplantation of osteoarticular tissues into injured areas, providing a sustainable solution to current age-related degenerative knee pathologies. It represents an innovative treatment designed to improve patients’ quality of life, reduce their degree of dependency, and contribute to lowering healthcare costs associated with current treatments.

Achieving such an ambitious overarching goal requires multidisciplinary collaboration among several companies (IZERTIS, JUNCÀ, DAN*NA, TECBIOCEL, SOLUTEX, READYCELL, and CARINSA) and research centres (LEITAT, IDONIAL, and VHIR) to address the project’s specific technical objectives.

This project is funded by the Centre for the Development of Industrial Technology (CDTI) and supported by the Ministry of Science, Innovation and Universities under the Science and Innovation Missions programme: (EXP 00132420 / MIG-20201046). The project will run from December 2020 to December 2023, with a total duration of 37 months.
 

​